FINWIRES · TerminalLIVE
FINWIRES

CSPC Pharmaceutical Drug Shows 'Favorable' Anti-tumor Profile in Study

By

CSPC Pharmaceutical Group (HKG:1093) said currently available clinical data for its drug candidate SYS6043 indicates it could become a treatment option for multiple tumor types, according to a Tuesday filing with the Hong Kong bourse.

According to the company, the medicine demonstrated "favorable anti-tumor activity" in subjects enrolled in an open-label, phase 1/2 clinical study in China.

Among the 533 evaluable patients, the objective response rate was 41.8% while the median duration of response stood at 6.9 months. The disease control rate among the patients was assessed at 81.4%.

Based on the results, the firm said it would advance related studies of the drug in ovarian cancer, breast cancer, and small cell lung cancer.

Related Articles

Asia

Tata Motors Passenger Vehicles' Total Sales Rise 42% in May

Tata Motors Passenger Vehicles' (NSE:TMPV, BOM:500570) total sales rose 42% to 59,790 units in May, against 42,040 units sold a year ago, according to a Monday filing to the Indian bourses.Total domestic sales in May also grew 42% to 59,090 units from 41,557 units a year earlier, the filing said.Of the total, electric vehicle sales jumped 85% year-on-year to 10,517 units from 5,685 units.

BOM:500570NSE:TMPV
Asia

Dian Tou Energy Acquires Baiyinhua Coal & Power for 11.1 Billion Yuan; Shares Down 4%

Inner Mongolia Dian Tou Energy (SHE:002128) fully acquired Baiyinhua Coal & Power for 11.1 billion yuan, according to a Tuesday disclosure on the Shenzhen bourse.The acquisition was made through share placement and capital injection.The company raised 4.50 billion yuan as part of the acquisition funds.The Chinese coal products maker's shares dropped 4% during the morning trade.

SHE:002128
Asia

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838